<?xml version='1.0' encoding='utf-8'?>
<document id="28753882"><sentence text="Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate."><entity charOffset="102-121" id="DDI-PubMed.28753882.s1.e0" text="Abiraterone Acetate" /></sentence><sentence text="Although statin use has been associated with favorable effects in various solid malignancies, no conclusive evidence is available at present" /><sentence text=" Statins are safe and inexpensive, and may synergize with novel antiandrogen agents abiraterone via pharmacokinetic interactions and decrease substrate availability for de novo androgen biosynthesis"><entity charOffset="84-95" id="DDI-PubMed.28753882.s3.e0" text="abiraterone" /><entity charOffset="177-185" id="DDI-PubMed.28753882.s3.e1" text="androgen" /><pair ddi="false" e1="DDI-PubMed.28753882.s3.e0" e2="DDI-PubMed.28753882.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28753882.s3.e0" e2="DDI-PubMed.28753882.s3.e1" /></sentence><sentence text="" /><sentence text="To determine whether statin use affects survival in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone"><entity charOffset="135-146" id="DDI-PubMed.28753882.s5.e0" text="abiraterone" /></sentence><sentence text="" /><sentence text="Medical records of patients with documented mCRPC between September 2011 and August 2016 were reviewed at multiple participating centers" /><sentence text=" This research was conducted in ten institutions, including both referral centers and local hospitals" /><sentence text=" A total of 187 patients receiving abiraterone for mCRPC between September 2011 and August 2016 were eligible for inclusion in this retrospective study"><entity charOffset="35-46" id="DDI-PubMed.28753882.s9.e0" text="abiraterone" /></sentence><sentence text="" /><sentence text="Patients were assessed for overall survival (OS), statin use at the time of treatment initiation, prostate-specific antigen (PSA) variations, and other variables of interest" /><sentence text=" Univariable and multivariable analysis was used to explore the association of variables of interest with OS and PSA declines" /><sentence text="" /><sentence text="Statin use was a significant prognostic factor for longer OS in univariable (hazard ratio [HR] 0" /><sentence text="51, 95% confidence interval [CI] 0" /><sentence text="37-0" /><sentence text="72; p&lt;0" /><sentence text="001) and multivariable analysis (HR 0" /><sentence text="40, 95% CI 0" /><sentence text="27-0" /><sentence text="59; p&lt;0" /><sentence text="001) and was significantly associated with PSA declines (&gt;50% decline at 12 wk: 72" /><sentence text="1% in statin users vs 38" /><sentence text="5% in non-users; p&lt;0" /><sentence text="001)" /><sentence text="" /><sentence text="Our study suggests a prognostic impact of statin use in patients receiving abiraterone for mCRPC"><entity charOffset="75-86" id="DDI-PubMed.28753882.s27.e0" text="abiraterone" /></sentence><sentence text=" The mechanism of this interaction warrants elucidation, but may include enhancement of the antitumor activity of abiraterone as well as cardioprotective effects"><entity charOffset="114-125" id="DDI-PubMed.28753882.s28.e0" text="abiraterone" /></sentence><sentence text="" /><sentence text="We assessed the effects of statin use in patients with advanced prostate cancer receiving abiraterone"><entity charOffset="90-101" id="DDI-PubMed.28753882.s30.e0" text="abiraterone" /></sentence><sentence text=" Patients treated with a statin plus abiraterone appeared to live longer than those treated with abiraterone only"><entity charOffset="37-48" id="DDI-PubMed.28753882.s31.e0" text="abiraterone" /><entity charOffset="97-108" id="DDI-PubMed.28753882.s31.e1" text="abiraterone" /><pair ddi="false" e1="DDI-PubMed.28753882.s31.e0" e2="DDI-PubMed.28753882.s31.e0" /><pair ddi="false" e1="DDI-PubMed.28753882.s31.e0" e2="DDI-PubMed.28753882.s31.e1" /></sentence><sentence text=" Since no negative drug-drug interaction is known and statins are widely used and inexpensive, further studies assessing the use of abiraterone plus statins are warranted"><entity charOffset="132-143" id="DDI-PubMed.28753882.s32.e0" text="abiraterone" /></sentence><sentence text="" /></document>